StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.16−0.04 (-1.82%)

Close on Nov 17, 2026Market cap $103.14MP/E –Yield –

Minerva Neurosciences cash

Cash and short-term investments held at the end of each period.

Minerva Neurosciences's cash was $75.27M at Jun 30, 2026. For fiscal 2025 it was $82.30M, up 285.3% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $128.16M in fiscal 2017.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$82.30M+285.3%
FY2024Dec 31, 2024$21.36M-47.8%
FY2023Dec 31, 2023$40.91M+13.4%
FY2022Dec 31, 2022$36.09M-40.6%
FY2021Dec 31, 2021$60.76M+139.6%
FY2020Dec 31, 2020$25.36M-44.7%
FY2019Dec 31, 2019$45.85M-47.9%
FY2018Dec 31, 2018$88.00M-31.3%
FY2017Dec 31, 2017$128.16M+54.3%
FY2016Dec 31, 2016$83.06M+157.9%
FY2015Dec 31, 2015$32.20M+73.7%
FY2014Dec 31, 2014$18.55M+919.9%
FY2013Dec 31, 2013$1.82M+807.7%
FY2012Dec 31, 2012$200.31K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$75.27M+393.6%
Q1 FY2026Mar 31, 2026$78.06M+351.5%
Q4 FY2025Dec 31, 2025$82.30M+285.3%
Q3 FY2025Sep 30, 2025$12.29M-53.7%
Q2 FY2025Jun 30, 2025$15.25M-50.6%
Q1 FY2025Mar 31, 2025$17.29M-50.3%
Q4 FY2024Dec 31, 2024$21.36M-47.8%
Q3 FY2024Sep 30, 2024$26.53M-43.4%
Q2 FY2024Jun 30, 2024$30.88M-40.4%
Q1 FY2024Mar 31, 2024$34.82M-3.2%
Q4 FY2023Dec 31, 2023$40.91M+13.4%
Q3 FY2023Sep 30, 2023$46.90M+16.6%
Q2 FY2023Jun 30, 2023$51.80M+4.1%
Q1 FY2023Mar 31, 2023$35.98M-34.5%
Q4 FY2022Dec 31, 2022$36.09M-40.6%
Q3 FY2022Sep 30, 2022$40.22M-38.7%
Q2 FY2022Jun 30, 2022$49.75M-33.0%
Q1 FY2022Mar 31, 2022$54.95M-31.4%
Q4 FY2021Dec 31, 2021$60.76M+139.6%
Q3 FY2021Sep 30, 2021$65.59M+101.7%
Q2 FY2021Jun 30, 2021$74.21M+110.5%
Q1 FY2021Mar 31, 2021$80.14M+113.6%
Q4 FY2020Dec 31, 2020$25.36M-44.7%
Q3 FY2020Sep 30, 2020$32.52M-45.7%
Q2 FY2020Jun 30, 2020$35.25M-49.1%
Q1 FY2020Mar 31, 2020$37.51M-52.6%
Q4 FY2019Dec 31, 2019$45.85M-47.9%
Q3 FY2019Sep 30, 2019$59.93M-38.6%
Q2 FY2019Jun 30, 2019$69.29M-36.1%
Q1 FY2019Mar 31, 2019$79.16M-34.6%
Q4 FY2018Dec 31, 2018$88.00M-31.3%
Q3 FY2018Sep 30, 2018$97.61M-26.6%
Q2 FY2018Jun 30, 2018$108.49M+39.9%
Q1 FY2018Mar 31, 2018$121.00M+41.7%
Q4 FY2017Dec 31, 2017$128.16M+54.3%
Q3 FY2017Sep 30, 2017$132.93M+44.7%
Q2 FY2017Jun 30, 2017$77.57M–
Q1 FY2017Mar 31, 2017$85.36M–
Q4 FY2016Dec 31, 2016$83.06M–
Q3 FY2016Sep 30, 2016$91.85M–

More Minerva Neurosciences figures

See a number that looks wrong?